Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CIDP patients switching to HyQvia: what drives the choice?

NCT ID NCT06538064

Disease control Sponsor: Takeda Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 30 adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who are switching to the treatment HyQvia. Researchers will use questionnaires and medical records to understand why patients chose to switch, how satisfied they are, and how the treatment affects their symptoms, daily life, and work. The goal is to gather real-world information on the use and outcomes of HyQvia in routine medical care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population is participants with a confirmed clinical diagnosis of CIDP, who are in the process of switching from any prior CIDP therapy to HyQvia for maintenance treatment of CIDP. The participants population will be comprised of both new users (Cohort A) and current users (Cohort B) of HyQvia.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged 18 years or older. * Investigator-confirmed documented diagnosis of CIDP of any type (e.g., typical, multifocal, focal, motor, sensory, or distal) according to the revised European Academy of Neurology and Peripheral Nerve Society (EAN/PNS) 2021 guidelines on the diagnosis and treatment of CIDP. * Participants must currently have a stable disease course (as per physician judgment) for at least 12 weeks. * Is considered a new user or current user of HyQvia- * New users (Cohort A) are participants on a CIDP treatment as of the date of enrollment, who intend to switch to HyQvia within 6 weeks after enrollment. * Current users (Cohort B) are participants on HyQvia as of the date of enrollment, who switched to HyQvia within the 6 weeks preceding the date of enrollment (the 6-week window may be extended depending on the recruitment progress). * Has provided written informed consent (for the main study). * Participant is willing to comply with the protocol requirement of non-standard of care (non-SOC) assessments (e.g., adjusted inflammatory neuropathy cause and treatment (INCAT) assessment). * Participants must be able to communicate fluently in their local language (if they participate in the optional qualitative participant interview \[sub-study\]. Exclusion Criteria: * Had any HyQvia use, defined as * any record of HyQvia use prior to enrollment for new users of HyQvia (Cohort A), and * any record of HyQvia use more than 6 weeks preceding the enrollment date (the 6-week window may be extended depending on the recruitment progress) for current users of HyQvia (Cohort B). * Without any prior treatment for CIDP. * Pregnant or breastfeeding. * Participants with known hypersensitivity to any component of HyQvia. * Has participated in an interventional clinical study within 30 days prior to enrollment or was scheduled to participate in an interventional clinical study during this study. * Has had major surgery within 12 weeks prior to enrollment, or has surgery planned during the time the participant is expected to participate in the study. Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgeries. * Received induction treatment for CIDP during the past 12 weeks. * Participant is identified by the investigator as being unable or unwilling to cooperate with the study procedures. * (Cohort A) only: Participants who do not initiate HyQvia treatment within 6 weeks after enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic inflammatory demyelinating polyradiculoneuropathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    15 sites in 3 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Arhus Universtitetshospital

    RECRUITING

    Aarhus N, 8200, Denmark

  • HSHS St. Elizabeths Hospital

    RECRUITING

    O'Fallon, Illinois, 62269, United States

  • Hawaii Pacific Neuroscience

    RECRUITING

    Honolulu, Hawaii, 96817, United States

  • Immanuel Klinik Rudersdorf

    RECRUITING

    Rüdersdorf, Brandenburg, 15562, Germany

  • Judisches Krankenhaus Berlin

    NOT_YET_RECRUITING

    Berlin, 13347, Germany

  • Katholisches Klinikum Bochum gGmbH

    RECRUITING

    Bochum, North Rhine-Westphalia, 44791, Germany

  • Neuro/Psych Sleep Clinic

    RECRUITING

    San Francisco, California, 94143, United States

  • Nova Clinical Research, LLC

    RECRUITING

    Bradenton, Florida, 34209, United States

  • Rigshospitalet

    RECRUITING

    København Ø, 2100, Denmark

  • Samir Macwan MD Inc

    RECRUITING

    Rancho Mirage, California, 92270, United States

  • Suncoast Neuroscience Associates, Inc.

    NOT_YET_RECRUITING

    St. Petersburg, Florida, 33713, United States

  • Universitaetsklinikum Giessen und Marburg GmbH Standort Marburg

    NOT_YET_RECRUITING

    Marburg, Hesse, 35043, Germany

  • University of Kansas Medical Center Research Institute, Inc.

    RECRUITING

    Kansas City, Kansas, 66160, United States

  • Wake Forest University - School of Medicine - Central

    RECRUITING

    Winston-Salem, North Carolina, 27157, United States

  • Yale School Of Medicine

    NOT_YET_RECRUITING

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.